Logo image of NXTD

NXT-ID INC (NXTD) Stock Fundamental Analysis

NASDAQ:NXTD - Nasdaq - Common Stock

2.42  -0.13 (-5.1%)

After market: 2.41 -0.01 (-0.41%)

Fundamental Rating

2

We assign a fundamental rating of 2 out of 10 to NXTD. NXTD was compared to 284 industry peers in the Software industry. The financial health of NXTD is average, but there are quite some concerns on its profitability. While showing a medium growth rate, NXTD is valued expensive at the moment.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

NXTD had negative earnings in the past year.
NXTD Yearly Net Income VS EBIT VS OCF VS FCFNXTD Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 0 -5M -10M

1.2 Ratios

Industry RankSector Rank
ROA -18.17%
ROE N/A
ROIC N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
NXTD Yearly ROA, ROE, ROICNXTD Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 0 -500 -1K

1.3 Margins

Industry RankSector Rank
OM -24.43%
PM (TTM) -68.5%
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
NXTD Yearly Profit, Operating, Gross MarginsNXTD Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 0 -500 -1K -1.5K -2K

More info and screens

5

2. Health

2.1 Basic Checks

Compared to 1 year ago, NXTD has more shares outstanding
Compared to 1 year ago, NXTD has an improved debt to assets ratio.
NXTD Yearly Shares OutstandingNXTD Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 10M 20M 30M 40M
NXTD Yearly Total Debt VS Total AssetsNXTD Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 10M 20M 30M 40M

2.2 Solvency

Based on the Altman-Z score of 0.73, we must say that NXTD is in the distress zone and has some risk of bankruptcy.
There is no outstanding debt for NXTD. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 0.73
ROIC/WACCN/A
WACCN/A
NXTD Yearly LT Debt VS Equity VS FCFNXTD Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 0 5M -5M 10M 15M 20M

2.3 Liquidity

NXTD has a Current Ratio of 4.54. This indicates that NXTD is financially healthy and has no problem in meeting its short term obligations.
NXTD has a Quick Ratio of 4.31. This indicates that NXTD is financially healthy and has no problem in meeting its short term obligations.
Industry RankSector Rank
Current Ratio 4.54
Quick Ratio 4.31
NXTD Yearly Current Assets VS Current LiabilitesNXTD Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2M 4M 6M 8M 10M

More info and screens

4

3. Growth

3.1 Past

NXTD shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -5778.71%.
The Revenue for NXTD has decreased by -20.92% in the past year. This is quite bad
NXTD shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 79.15% yearly.
EPS 1Y (TTM)-5778.71%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-3309.14%
Revenue 1Y (TTM)-20.92%
Revenue growth 3Y-10.65%
Revenue growth 5Y79.15%
Sales Q2Q%-9.73%

3.2 Future

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
Based on estimates for the next years, NXTD will show a quite strong growth in Revenue. The Revenue will grow by 18.00% on average per year.
EPS Next Y87.07%
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year-11.33%
Revenue Next 2Y18%
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
NXTD Yearly Revenue VS EstimatesNXTD Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 5M 10M 15M 20M
NXTD Yearly EPS VS EstimatesNXTD Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 -10 -20 -30

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

NXTD reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year NXTD is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
NXTD Price Earnings VS Forward Price EarningsNXTD Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA -3.27
NXTD Per share dataNXTD EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

No dividends for NXTD!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

NXT-ID INC

NASDAQ:NXTD (3/1/2022, 8:20:15 PM)

After market: 2.41 -0.01 (-0.41%)

2.42

-0.13 (-5.1%)

Chartmill FA Rating
GICS SectorInformation Technology
GICS IndustryGroupSoftware & Services
GICS IndustrySoftware
Earnings (Last)N/A N/A
Earnings (Next)N/A N/A
Inst Owners0%
Inst Owner Change0%
Ins Owners154.62%
Ins Owner Change0%
Market Cap21.54M
Analysts43.33
Price TargetN/A
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DP0%
Div Incr YearsN/A
Div Non Decr YearsN/A
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 2.11
P/FCF N/A
P/OCF N/A
P/B 0.63
P/tB N/A
EV/EBITDA -3.27
EPS(TTM)-1.31
EYN/A
EPS(NY)-2.84
Fwd EYN/A
FCF(TTM)N/A
FCFYN/A
OCF(TTM)N/A
OCFYN/A
SpS1.14
BVpS3.85
TBVpSN/A
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -18.17%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM -24.43%
PM (TTM) -68.5%
GM N/A
FCFM N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3Y0%
ROICexcg growth 5Y0%
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0.27
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 4.54
Quick Ratio 4.31
Altman-Z 0.73
F-Score3
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-5778.71%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-3309.14%
EPS Next Y87.07%
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)-20.92%
Revenue growth 3Y-10.65%
Revenue growth 5Y79.15%
Sales Q2Q%-9.73%
Revenue Next Year-11.33%
Revenue Next 2Y18%
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1YN/A
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1YN/A
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1YN/A
OCF growth 3YN/A
OCF growth 5YN/A